My Crossword Maker Logo
Powered by BrightSprout
Save Status:
or to save your progress. The page will not refresh.
Controls:
SPACEBAR SWITCHES TYPING DIRECTION
Answer Key:
Edit a Copy:
Make Your Own:
Crucigrama Sopa de Letras Hoja de Trabajo
Calificar este Puzzle:
Log in or sign up to rate this puzzle.

The cynical scribe's guide to the top 25 of infectious disease testing - Spring 2022 edition

Looking for actionable market intelligence on the US and Europe. Contact [email protected] for a zoom demo.
Horizontales
We're #14 in the US and #17 in Europe...the biggest of the Danaher diagnostic companies. We sell robotics, AST, and viral immunoassays.
We're #18 in the US and #31 in Europe. We're the American swab and media team.
We're #5 in Europe but only #15 in the US, because the FDA was slow to approve our Healgen rapid antigen tests.
We're #7 in the US and #12 in Europe. We sold a lot of rapid antigen tests in 2020, then a lot less in 2021.
We're #3 in the US and #10 in Europe. Who says you can't herd cats? We've trained our felines to run small covid panels, STI tests, and viral loads.
We're #1 in Europe and #5 in the US. If the FDA hadn't been so slow to approve our SD fast antigen kits, we'd be #1 on both sides of the Atlantic.
We're #9 in both Europe and the US. We make our Covid money four ways: open-system PCR, serology, robotics, and lab services
We were #24 in the US and #28 in Europe last year, but we're rising fast. We're the apex predator of NGS markets; our patents are expiring soon, so no rest for the weary.
We're #8 in Europe and #6 in the US. We're hard to beat in AST and syndromic panels.
We're #14 in Europe and #16 in the US. We took our cats out of the blood bank and into Iberia's Covid labs.
We're #8 in the US and #21 in Europe. Our revenues were $1.7b in 2020, and about the same last year. Then we took in $1b in 1Q22.
We're #19 in both the US and Europe. We're the Italian swab & media team.
We were #23 in Europe last year, but we don't sell much in the US. We make the Siemens rapid antigen tests.
We're #17 in the US and #18 in Europe. We're the incumbent power of ddPCR instrumentation and viral QC.
We're #13 in the US and #24 in Europe. We just got acquired cheap - barely three times revenues
Verticales
We're #4 in the US and #7 in Europe. We're their 2nd-biggest diagnostic company, but were the most profitable. So Danaher likes us best.
We're #6 in Europe but just getting started in the US. Basel has been good to us, but we don't just fish in the Rhine. We have dealers on every river.
We're #11 in the US and #16 in Europe. We used our Covid windfall to buy a little bit of Texas - a la carte syndromic panels.
We're #10 in the US, still scarce in Europe. We've placed 250,000 cheap molecular Covid instruments, but 75-80% are nearly dormant.
We don't sell in the US but we were #1 in European Covid revenue last year, which all came from one British customer - an embarrassed NHS.
We're #2 in the US and #3 in Europe. Despite appearances, we didn't pay Trump to sell our rapid antigen tests.
We're #12 in the US and #15 in Europe. We make our Covid money six ways: hi-throughput PCR, syndromic panels, rapid antigen, robotics, extraction kits, and NGS.
We're #11 in Europe and #20 in the US. We're Biorad's best friend in Korea.
We're #1 in the US and #4 in Europe. We're the team to be in hi throughput PCR Covid and transport media. Also #3 in bacteriology
We're #32 in the US and #22 in Europe. The Belfast team is the biggest family-owned IVD company in this puzzle.